Differentiating Between Acute Decompensated Aortic Stenosis and Myocardial Infarction.


Journal

Cardiovascular revascularization medicine : including molecular interventions
ISSN: 1878-0938
Titre abrégé: Cardiovasc Revasc Med
Pays: United States
ID NLM: 101238551

Informations de publication

Date de publication:
10 2022
Historique:
received: 26 02 2022
revised: 31 03 2022
accepted: 11 04 2022
pubmed: 10 5 2022
medline: 28 9 2022
entrez: 9 5 2022
Statut: ppublish

Résumé

Patients with aortic stenosis (AS) are susceptible to myocardial ischemia and often present acutely, making it challenging to differentiate between a type 1 NSTEMI and acute decompensated aortic stenosis. This study aims to evaluate the diagnostic accuracy of Troponin T (TnT) (>5 fold above the upper limit of normal), ischemic ECG and angina, to predict a type 1 non-ST elevation myocardial infarction (NSTEMI) and obstructive coronary artery disease (CAD) among patients with severe AS and acute presentations. Patients with severe AS and acute symptoms: angina (Canadian Cardiovascular Society Class 3/4), dyspnea (New York Heart Association 4) and/or syncope were included. The endpoints were a type 1 NSTEMI defined by the presence of a coronary thrombus or > 90% stenosis and obstructive CAD defined as >70% stenosis, by computed tomography (CT) and/or invasive coronary angiography (ICA). Out of 273 patients, 6.2% had a type 1 NSTEMI. Positive TnT, ischemic ECG and angina demonstrated negative predictive values of 95%, 94% and 97% respectively and positive predictive values of 12%, 9% and 13% respectively. Specificity increased with all three metrics (95%), whilst sensitivity and positive predictive value reduced (18% and 19% respectively). 39.2% of patients had obstructive CAD. Positive TnT, ischemic ECG and angina demonstrated sensitivity of 64%, 34% and 41% respectively and specificity of 57%, 77% and 77% respectively. Angina, ischemic ECG and positive TnT are common among patients with AS presenting acutely and often not associated with a type 1 NSTEMI. These metrics, if positive, cannot reliably differentiate between a type 1 NSTEMI and acute decompensated AS. Coronary imaging using either CT or ICA is necessary to make a definitive diagnosis of a type 1 NSTEMI in patients with severe AS.

Sections du résumé

BACKGROUND
Patients with aortic stenosis (AS) are susceptible to myocardial ischemia and often present acutely, making it challenging to differentiate between a type 1 NSTEMI and acute decompensated aortic stenosis. This study aims to evaluate the diagnostic accuracy of Troponin T (TnT) (>5 fold above the upper limit of normal), ischemic ECG and angina, to predict a type 1 non-ST elevation myocardial infarction (NSTEMI) and obstructive coronary artery disease (CAD) among patients with severe AS and acute presentations.
METHODS
Patients with severe AS and acute symptoms: angina (Canadian Cardiovascular Society Class 3/4), dyspnea (New York Heart Association 4) and/or syncope were included. The endpoints were a type 1 NSTEMI defined by the presence of a coronary thrombus or > 90% stenosis and obstructive CAD defined as >70% stenosis, by computed tomography (CT) and/or invasive coronary angiography (ICA).
RESULTS
Out of 273 patients, 6.2% had a type 1 NSTEMI. Positive TnT, ischemic ECG and angina demonstrated negative predictive values of 95%, 94% and 97% respectively and positive predictive values of 12%, 9% and 13% respectively. Specificity increased with all three metrics (95%), whilst sensitivity and positive predictive value reduced (18% and 19% respectively). 39.2% of patients had obstructive CAD. Positive TnT, ischemic ECG and angina demonstrated sensitivity of 64%, 34% and 41% respectively and specificity of 57%, 77% and 77% respectively.
CONCLUSIONS
Angina, ischemic ECG and positive TnT are common among patients with AS presenting acutely and often not associated with a type 1 NSTEMI. These metrics, if positive, cannot reliably differentiate between a type 1 NSTEMI and acute decompensated AS. Coronary imaging using either CT or ICA is necessary to make a definitive diagnosis of a type 1 NSTEMI in patients with severe AS.

Identifiants

pubmed: 35534348
pii: S1553-8389(22)00176-2
doi: 10.1016/j.carrev.2022.04.003
pii:
doi:

Substances chimiques

Troponin T 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

13-17

Subventions

Organisme : British Heart Foundation
ID : FS/19/48/34523
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Kush Patel reports financial support was provided by Edwards Lifesciences Corp. Kush Patel reports financial support was provided by British Heart Foundation. Francesca Pugliese reports financial support was provided by Siemens Healthineers. Michael Mullen reports financial support was provided by Edwards Lifesciences Corp. Michael Mullen reports financial support was provided by Abbott Vascular. Andreas Baumbach reports financial support was provided by Abbott Vascular. Andreas Baumbach reports financial support was provided by Astra Zeneca. Andreas Baumbach reports financial support was provided by Sinomed. Andreas Baumbach reports financial support was provided by Microport. Andreas Baumbach reports financial support was provided by Cardinal Health. Andreas Baumbach reports financial support was provided by KSH.

Auteurs

Kush P Patel (KP)

Institute of cardiovascular science, University College London, London, United Kingdom; Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom.

Krishnaraj Rathod (K)

Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom; Centre for Cardiovascular Medicine and Devices, William Harvey Research Institute, Queen Mary University of London, United Kingdom.

Mohammed Akhtar (M)

Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom.

Daniel A Jones (DA)

Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom; Centre for Cardiovascular Medicine and Devices, William Harvey Research Institute, Queen Mary University of London, United Kingdom.

Mick Ozkor (M)

Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom.

Simon Kennon (S)

Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom.

Anthony Mathur (A)

Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom; Centre for Cardiovascular Medicine and Devices, William Harvey Research Institute, Queen Mary University of London, United Kingdom; Yale University School of Medicine, New Haven, CT. USA.

Francesca Pugliese (F)

Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom; Centre for Advanced Cardiovascular imaging, William Harvey Research Institute, Queen Mary University of London, United Kingdom.

Michael J Mullen (MJ)

Institute of cardiovascular science, University College London, London, United Kingdom; Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom.

Andreas Baumbach (A)

Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom; Centre for Cardiovascular Medicine and Devices, William Harvey Research Institute, Queen Mary University of London, United Kingdom; Yale University School of Medicine, New Haven, CT. USA. Electronic address: a.baumbach@qmul.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH